Over the last several decades, two checkpoints, the cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and PD1 pathways, have been highlighted for their importance in cancer immunology with the development of checkpoint inhibitors as effective treatments for multiple cancers, through the blockade of these pathways. This evidence concerns the gene CTLA4 and cancer.